Molecular Partners AG (MOLN) has a current Price-to-Book (P/B) ratio of 1.31. Compared to its 3-year average P/B ratio of 0.94, the current P/B ratio is approximately 39.70% higher. Relative to its 5-year average P/B ratio of 1.97, the current P/B ratio is about -33.54% higher. Molecular Partners AG (MOLN) has a Forward Free Cash Flow (FCF) yield of approximately -42.66%. Compared to its 3-year average FCF yield of -40.49%, the current FCF yield is approximately 5.37% lower. Relative to its 5-year average FCF yield of -15.98%, the current FCF yield is about 166.91% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MOLN competitors is 10.35, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MOLN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MOLN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MOLN currently overvalued or undervalued?

What is Molecular Partners AG (MOLN) fair value?

MOLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Molecular Partners AG (MOLN) is between to according to relative valuation method.

How does MOLN's valuation metrics compare to the industry average?

The average P/S ratio for MOLN's competitors is 10.35, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Molecular Partners AG (MOLN) as of Mar 03 2026?

As of Mar 03 2026, Molecular Partners AG (MOLN) has a P/B ratio of 1.31. This indicates that the market values MOLN at 1.31 times its book value.

What is the current FCF Yield for Molecular Partners AG (MOLN) as of Mar 03 2026?

As of Mar 03 2026, Molecular Partners AG (MOLN) has a FCF Yield of -42.66%. This means that for every dollar of Molecular Partners AG's market capitalization, the company generates -42.66 cents in free cash flow.

What is the current Forward P/E ratio for Molecular Partners AG (MOLN) as of Mar 03 2026?

As of Mar 03 2026, Molecular Partners AG (MOLN) has a Forward P/E ratio of -3.11. This means the market is willing to pay $-3.11 for every dollar of Molecular Partners AG's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Molecular Partners AG (MOLN) as of Mar 03 2026?

As of Mar 03 2026, Molecular Partners AG (MOLN) has a Forward P/S ratio of 0.00. This means the market is valuing MOLN at $0.00 for every dollar of expected revenue over the next 12 months.

MOLN Valuation